Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
Status:
Completed
Trial end date:
2016-12-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out whether treatment to prevent kidney rejection
with belatacept in presence of Thymoglobulin induction and withdrawal of steroids will result
in less delayed graft function or "sleepy kidney" after transplant than that seen in patients
who get tacrolimus as their main drug to prevent rejection instead of belatacept. The
investigators will also look at whether patients who get belatacept have the same, lesser or
more problems that those who get tacrolimus.